Contact Us: 734-712-3456
Treatment   Allergy and Immunology
Trial Title   A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 mg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma
Description of Research   The purpose of this research study is to determine if a medication called budesonide pMDI 160 µg (micrograms) twice a day is effective and safe in treating asthmatic children aged 6 to less than 12 years and if so, how it compares with placebo. A placebo looks like a pMDI inhaler but contains no active medication.
Study Number   HSR-10-1120
Inclusion/Notes   For patients between the ages of 6 and 12 years (has not had his/her 12th birthday), has been diagnosed with asthma and has been taking an inhaled corticosteroid medication for his/her asthma for at least 4 weeks. Examples of inhaled corticosteroid medications are: ALVESCO®, ASMANEX®, QVAR®, FLOVENT®, PULMICORT®.
Principal Investigator   Jeffrey Leflein, MD
Contact Name   Pat Lezak, CCRC
Phone   (734) 528-0477